How Treating Allergic Rhinitis Can Greatly Improve Asthma Control: Key Insights from Scientific Research

Asthma and allergic rhinitis are two common respiratory diseases that often occur together, making life difficult for many people. But new research shows that treating allergic rhinitis can significantly improve asthma symptoms and overall quality of life. This article explains the findings of a comprehensive scientific review in simple terms, helping everyone understand the importance of managing allergic rhinitis to control asthma better.

Understanding Asthma and Allergic Rhinitis

What is Asthma?

Asthma is a long-term lung disease that causes breathing problems. Symptoms include:

  • Wheezing (a whistling sound when breathing)
  • Shortness of breath
  • Chest tightness
  • Coughing, especially at night or early morning

Asthma can vary in severity. For some, it is a mild inconvenience, while for others, it can be life-threatening. According to the reviewed study, the annual prevalence of asthma in general practice ranges from 3% to 6.5%. This means that out of every 100 people visiting a doctor, around 3 to 6 might have asthma. Asthma affects both children and adults, and its prevalence has been rising over the past few decades.

What is Allergic Rhinitis?

Allergic rhinitis, often called hay fever, is caused by allergies. Symptoms include:

  • Sneezing
  • Runny or stuffy nose
  • Itchy nose and eyes
  • Watery eyes

The study highlights that allergic rhinitis affects between 0.4% and 4.1% of the general population annually. In children, the prevalence is even higher, with 5.9% of children in Dutch general practice diagnosed with allergic rhinitis. This condition is triggered by allergens like pollen, dust mites, pet dander, and mold.

Why Do Asthma and Allergic Rhinitis Often Occur Together?

The review found that up to 55% of people with asthma also have allergic rhinitis, and 20-40% of allergic rhinitis patients also have asthma. Both conditions are linked because they affect the same airway system – from the nose to the lungs. This connection is explained by the "unified airway theory," which suggests that inflammation in the upper airway (nose) can trigger inflammation in the lower airway (lungs). This makes it harder to control asthma symptoms in patients who also have allergic rhinitis.

The study mentions that patients with both conditions often experience more severe asthma symptoms, greater difficulty in controlling asthma, and a significant reduction in quality of life.

Why Treating Allergic Rhinitis Matters for Asthma Patients

The research aimed to see how treatments for allergic rhinitis affect asthma outcomes. Researchers reviewed 33 high-quality studies involving 5,987 patients, including children and adults, to find out which medications worked best.

Treating allergic rhinitis might seem unrelated to asthma, but the study shows otherwise. Managing allergic rhinitis can improve lung function, reduce asthma symptoms, and enhance the quality of life for people with both conditions.

Types of Medications Studied

The review focused on three main types of medications used to treat allergic rhinitis:

  1. Antihistamines – These reduce allergy symptoms like sneezing and runny nose by blocking histamine, a substance that causes allergic reactions.
  2. Corticosteroids – These reduce inflammation in the airways, making it easier to breathe.
  3. Leukotriene Receptor Antagonists (LRA) – These block leukotrienes, chemicals that cause inflammation in the lungs, often used for asthma treatment.

Each of these medications was compared to placebos (inactive substances) or other asthma medications to see their effectiveness in improving asthma outcomes. 

Key Findings from the Review

1. Antihistamines Show the Most Improvement in Asthma Symptoms

  • 9 out of 11 studies showed significant improvement in asthma symptoms when patients used antihistamines.
  • Quality of life improved by 0.9 points on a 7-point scale, which is considered moderate.
  • Antihistamines also reduced the need for emergency asthma medication by 12-15%.

The review highlighted that antihistamines, especially second-generation antihistamines like cetirizine and loratadine, were more effective than other medications in improving asthma symptoms. These medications helped reduce nighttime and daytime asthma symptoms, which are crucial for better asthma control.

For example, one study reported that patients using antihistamines had a significant improvement in their Asthma Quality of Life Questionnaire scores, from 4.4 to 3.5 points, with a minimal important difference being 0.5 points. Another study showed that the RHINASTHMA global summary score improved from 28 to 16 in patients using levocetirizine compared to a smaller improvement in the placebo group.

2. Corticosteroids Are Effective but Show Mixed Results

  • 7 out of 14 studies reported significant improvement in asthma symptoms with corticosteroids.
  • A high-dose group improved lung function by 25 liters per minute, but lower doses showed smaller improvements.
  • Corticosteroids performed better than LRAs but slightly less effective than antihistamines for asthma symptom control.

Intranasal corticosteroids, such as fluticasone and budesonide, were found to be beneficial in reducing airway inflammation and improving asthma symptoms. However, the review noted that while some studies showed significant improvements in lung function and asthma control, others did not find clinically relevant changes. This means that while corticosteroids help, their effectiveness may depend on the dosage and individual patient response.

For instance, one study reported that high-dose fluticasone improved peak expiratory flow rates by 25 liters per minute, which is significant. However, in another study, the quality of life improved by only 0.2 points on a 7-point scale, which is not considered clinically relevant.

3. Leukotriene Receptor Antagonists Showed the Least Benefit

  • Only 2 out of 7 studies found significant improvements in asthma symptoms with LRAs.
  • Lung function improved by 20 liters per minute in one study, but others showed no significant changes.
  • LRAs were less effective compared to antihistamines and corticosteroids.

Leukotriene receptor antagonists, such as montelukast, were found to have limited effectiveness in improving asthma symptoms in patients with allergic rhinitis. The review highlighted that while LRAs are commonly used in asthma management, they might not be the best choice for patients with both asthma and allergic rhinitis.

One study reported that the percentage of symptom-free days increased from 5.3% to 20.6% with topical corticosteroids, compared to 6.8% to 23.4% with LRAs. However, the improvement with LRAs was not as significant as with corticosteroids.

Impact of Medications on Quality of Life

Quality of life is an important measure for patients with chronic conditions like asthma and allergic rhinitis. The review found that:

  • Antihistamines: Improved quality of life by up to 12 points on a 100-point scale.
  • Corticosteroids: Improved quality of life by 6-10 points, but some results were not clinically significant.
  • LRAs: Showed little to no improvement in quality of life for asthma patients.

The improvement in quality of life was more consistent with antihistamines compared to corticosteroids and LRAs. Patients reported fewer asthma symptoms, better sleep, and less need for rescue medication when using antihistamines.

Statistics Highlighting the Impact of Allergic Rhinitis Treatment on Asthma

The review provided several important statistics that highlight the impact of treating allergic rhinitis on asthma outcomes:

  • Asthma prevalence in general practice: 3% to 6.5% annually.
  • Allergic rhinitis prevalence: 0.4% to 4.1% annually.
  • Co-occurrence rates: Up to 55% in asthma patients and 20-40% in allergic rhinitis patients.
  • Quality of life improvement: Up to 12 points with antihistamines.
  • Lung function improvement: Up to 25 liters per minute with corticosteroids.
  • Reduction in emergency medication use: 12-15% with antihistamines.

These statistics show that allergic rhinitis is not just an annoying allergy but a significant factor in asthma management. Treating allergic rhinitis can lead to better asthma control, fewer symptoms, and an improved quality of life.

How Does Treating Allergic Rhinitis Improve Asthma?

The review found several reasons why treating allergic rhinitis helps asthma patients:

  • Better nasal function: Helps filter and condition the air before it reaches the lungs.
  • Reduced inflammation: Less inflammation in the nose leads to less inflammation in the lungs.
  • Improved breathing: Reducing nasal congestion improves overall airflow.

The study explained that nasal obstruction due to allergic rhinitis can lead to mouth breathing, which exposes the lungs to colder, drier air, worsening asthma symptoms. Treating nasal symptoms helps restore normal breathing and reduce asthma flare-ups.

Practical Tips for Asthma Patients with Allergic Rhinitis

  • Use Antihistamines Regularly: Especially during allergy seasons.
  • Follow Your Doctor’s Advice on Corticosteroids: Ensure you take the correct dose.
  • Avoid Triggers: Pollen, dust, and pet dander can worsen symptoms.
  • Monitor Your Symptoms: Keep track of asthma symptoms, especially during allergy seasons.

Challengesand Limitations Noted in the Review

  • Some studies used different ways to measure asthma symptoms, making it hard to compare results.
  • Most improvements in asthma symptoms were statistically significant but not always clinically meaningful.
  • Leukotriene receptor antagonists showed little benefit for asthma patients with allergic rhinitis.
  • More research is needed, especially on new treatments like immunotherapy.

The review noted that many studies used different scales and methods to measure asthma symptoms, which made it difficult to compare results. Also, while some improvements were statistically significant (meaning they were not due to chance), they were not always clinically significant (meaning they might not make a big difference in daily life).

What This Means for Patients and Doctors

The review highlights that:

  • Antihistamines should be the first choice for patients with both asthma and allergic rhinitis.
  • Corticosteroids are also effective, especially in higher doses.
  • Leukotriene receptor antagonists might not be worth considering for asthma control in these patients.

Doctors should consider treating allergic rhinitis aggressively in asthma patients to improve overall outcomes. Patients should be aware that managing their allergies is a crucial part of controlling asthma.

Future Research Directions

The review calls for:

  • More research on immunotherapy for patients with asthma and allergic rhinitis.
  • Standardized methods to measure asthma symptoms in clinical trials.
  • Focus on quality of life improvements, not just symptom control.

The review emphasized the need for future studies to use standardized measures for asthma outcomes and to focus on how treatments improve patients’ daily lives. Immunotherapy, a newer treatment option, also needs more research to understand its role in managing both conditions.

Conclusion

If you have asthma and allergic rhinitis, managing your allergy symptoms can significantly improve your asthma control and quality of life. This review provides strong evidence that antihistamines and corticosteroids are the best options for asthma patients with allergic rhinitis. Talk to your doctor about the best treatment plan for you, and don’t underestimate the impact of allergy management on your asthma health.

(This article is based entirely on the study “The effect of allergic rhinitis treatment on asthma control: a systematic review” published in npj Primary Care Respiratory Medicine (2025)

Comments

Post a Comment

Popular posts from this blog

Understanding Allergic Asthma: The Role of Biomarkers in Predicting Severity

Introduction Allergic asthma is a chronic condition that affects millions of people worldwide. It occurs when allergens trigger inflammation and constriction in the airways, leading to symptoms such as coughing, wheezing, shortness of breath, and chest tightness. While asthma severity varies from person to person, predicting its progression remains a challenge. Recent research has focused on biomarkers—biological indicators found in blood and tissue—that can help doctors assess asthma severity more accurately. A study titled "Assessing Serum and Biopsy Biomarkers for Predicting Allergic Asthma Severity" explores how these biomarkers can improve diagnosis and treatment. In this blog, we’ll break down the findings of this study in simple terms, discussing: What allergic asthma is and why it’s hard to predict The role of biomarkers in understanding asthma Key findings from the study How these findings can help in asthma management. What Is Allergic Asthma? Allergic as...
Read more

New Hope for Seniors with Severe Asthma: How Mepolizumab is Making Breathing Easier

I ntroduction Asthma is a chronic respiratory disease that affects millions of people worldwide. While it is often associated with younger individuals, asthma remains a significant health burden among the elderly . Older adults with severe asthma face unique challenges , including delayed diagnosis, multiple comorbidities, and increased medication dependence. Severe asthma, especially in older patients, is difficult to manage due to age-related immune system changes, lung function decline, and medication side effects . Traditional treatments such as inhaled corticosteroids and bronchodilators may be less effective in elderly patients, making biologic therapies like mepolizumab an attractive alternative. The REDES study is one of the few real-world studies that evaluates the effectiveness and safety of mepolizumab in elderly patients (≥65 years old) with severe eosinophilic asthma . This blog will delve into the study findings, explain mepolizumab’s mechanism of action , explore a...
Read more
Asthma is one of the most common diseases affecting children in the United Kingdom. Many families struggle with managing asthma symptoms, which can often lead to hospital visits, especially during severe attacks. A surprising new study has found that the UK Soft Drinks Industry Levy, introduced to reduce sugar consumption, has also led to a significant drop in childhood hospital admissions for asthma. This article explains the key findings of the study, why they matter, and how reducing sugar intake may benefit children’s health beyond preventing obesity. What Is the UK Soft Drinks Industry Levy? The UK Soft Drinks Industry Levy, often called the sugar tax, was announced in March 2016 and implemented in April 2018. It was designed to reduce the amount of sugar in soft drinks by encouraging manufacturers to reformulate their products. Drinks with more than 5 grams of sugar per 100 milliliters were taxed, with a higher tax for those with more than 8 grams of sugar per 100 milliliters. Dr...
Read more